Gold bars to be exempt from tariffs, White House clarifies
Radiopharm Theranostics Ltd announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for RAD101, their novel imaging agent for metastatic cancers. The company disclosed the news in a public notice to the Australian Securities Exchange on June 11, 2025, which was also filed with the SEC.
The Fast Track program is designed to expedite the development and review of drugs intended to treat serious conditions and fill an unmet medical need. The designation can lead to a faster approval process, thereby getting important new drugs to patients earlier.
The Melbourne-based pharmaceutical company, which specializes in the development of radiopharmaceuticals, provided the announcement as part of their monthly report to the SEC. The report states that the information it contains, including the attached public notice, is not to be considered "filed" for purposes of the Exchange Act and will not be incorporated by reference into any filing of the Securities Act unless specifically referenced in such filing.
The granting of Fast Track status by the FDA is a significant milestone for Radiopharm Theranostics and for patients awaiting new advancements in the imaging of metastatic diseases. This development could potentially streamline the clinical trial process for RAD101, potentially bringing it to market more quickly if the trials are successful.
The company’s filing with the SEC ensures transparency and provides investors and the public with verifiable information regarding its developments. Radiopharm Theranostics’ focus on innovative solutions in the pharmaceutical preparations sector is evidenced by this latest achievement in its pipeline of diagnostic and therapeutic products.
Investors and interested parties can find the full text of the public notice attached to the company’s SEC filing, which outlines the details of the FDA’s Fast Track designation for RAD101. The company’s progress can be followed through its filings and announcements to the Australian Securities Exchange and the SEC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.